Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Duration of Antibiotic Therapy Evaluation Study in Acute Cholangitis (DATES-AC): An Open-Label, Multicenter, Randomized Non-Inferiority Trial Comparing Short-Course Versus Standard-Course Antibiotic Therapy After ERCP With Early Intravenous-to-oral Switch in Patients With Acute Cholangitis (DATES-AC)

11. November 2026 aktualisiert von: Seoul National University Hospital

Acute cholangitis is an infection of the bile ducts, usually caused by a blockage that prevents bile from flowing normally. It can lead to serious complications if not treated promptly. Treatment generally includes antibiotics and drainage of the blocked bile duct, usually through a procedure called endoscopic retrograde cholangiopancreatography (ERCP).

Although antibiotics are essential for treating acute cholangitis, the optimal duration of antibiotic treatment after successful bile duct drainage remains uncertain. Current guidelines generally recommend 4 to 7 days of antibiotic treatment. However, shorter treatment may be sufficient after the source of infection has been effectively controlled, potentially reducing unnecessary antibiotic exposure, side effects, hospital stay, and healthcare costs.

The purpose of this study is to determine whether a shorter course of antibiotic treatment (4 days) is as effective as the standard course (7 days) in patients with moderate to severe acute cholangitis who have undergone successful bile duct drainage.

This is a multicenter, randomized, open-label study involving adults aged 19 years or older with moderate to severe acute cholangitis. Patients whose bile duct obstruction has been successfully relieved by ERCP within one day of hospital admission and who meet the study eligibility criteria may participate. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups.

The short-course group will receive antibiotics for a total of 4 days, while the standard-course group will receive antibiotics for a total of 7 days. In both groups, intravenous antibiotics will initially be given for at least 2 days. Patients who are clinically stable and able to take oral medication will be switched to oral antibiotics as early as possible. Antibiotic selection may be adjusted according to bacterial culture results and antibiotic susceptibility testing. If the initial antibiotics are found to be ineffective, or if the patient's clinical condition requires additional treatment, the antibiotics may be changed or extended to ensure patient safety.

The primary outcome is the clinical cure rate within 14 days after randomization. Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Secondary outcomes include recurrence of cholangitis between days 14 and 30 among patients who initially achieve clinical cure, all-cause mortality within 30 days, total duration of antibiotic use, and patient-reported health status and satisfaction with treatment. The incidence of adverse events within 14 days will also be evaluated. Additional assessments will compare hospital stay and total treatment costs between the two groups.

Participants will be followed up at approximately 14 and 30 days after randomization to assess treatment outcomes, recurrence of infection, additional antibiotic use, and safety.

This study aims to provide evidence on whether a 4-day antibiotic treatment strategy, combined with early conversion from intravenous to oral antibiotics after successful bile duct drainage, can achieve comparable treatment outcomes to the standard 7-day regimen. The findings may help establish a more appropriate antibiotic treatment strategy for patients with acute cholangitis while reducing unnecessary antibiotic exposure and its associated burden.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

  • 1. Empirical IV Antibiotics Ceftriaxone + Metronidazole
  • 2. Culture-directed IV Antibiotics Ciprofloxacin Piperacillin/Tazobactam Ertapenem Meropenem
  • 3. PO Antibiotics Cefpodoxime proxetil Amoxicillin/Clavulanate

Studientyp

Interventionell

Einschreibung (Geschätzt)

330

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Gyeonggi-do
      • Ansan, Gyeonggi-do, Südkorea, 15355
        • Korea University Ansan Hospital
        • Kontakt:
      • Seongnam-si, Gyeonggi-do, Südkorea, 13620
        • Seoul National University Bundang Hospital
        • Kontakt:
    • Seoul
      • Seoul, Seoul, Südkorea, 03080
        • Seoul National University Hospital
        • Kontakt:
      • Seoul, Seoul, Südkorea, 07061
        • Seoul Metropolitan Government Seoul National University Boramae Medical Center
        • Kontakt:
      • Seoul, Seoul, Südkorea, 04763

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

19 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients who voluntarily agree to participate in the study and provide written informed consent after receiving a full explanation of the study.
  • Patients who meet the diagnostic criteria for suspected or definite acute cholangitis according to the Tokyo Guidelines 2018 (TG18), regardless of whether the underlying cause is benign or malignant.
  • Patients with moderate or severe acute cholangitis according to the TG18 severity grading criteria.
  • Patients who have undergone successful biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) within one calendar day of hospital admission, resulting in relief of biliary obstruction.

Exclusion Criteria:

  • Circulatory failure requiring vasopressor support at the time of ERCP.

  • Persistent or newly developed hypothermia (body temperature below 35°C) between hospital admission and screening.

  • Patients requiring intensive care unit (ICU) treatment.

  • Use of antibiotics within 7 days before hospital admission.

  • Use of systemic antibiotics for 7 days or longer within 90 days before study enrollment for an infection unrelated to the current episode of acute cholangitis.

  • History of recurrent acute cholangitis within the previous 3 months.

  • Complex biliary strictures classified as Bismuth type II or higher.

  • Biliary obstruction of unknown cause.

  • Acute cholangitis caused by dysfunction of a distal biliary stent when the stent was inserted less than 30 days before study enrollment.

  • Complications associated with acute cholangitis present at the time of study enrollment, including acute cholecystitis, acute pancreatitis, liver abscess, or intra-abdominal abscess.

  • Presence of an infection other than acute cholangitis at the time of study enrollment.

  • Patients at high risk of infective endocarditis caused by Gram-positive bacteria, including those with prosthetic heart valves, congenital heart disease, or a previous history of infective endocarditis.

  • Complications following ERCP, including perforation, bleeding, severe post-ERCP pancreatitis, or cardiopulmonary complications related to sedation.

  • Altered upper gastrointestinal anatomy due to previous upper abdominal surgery, except for Billroth I gastrectomy.

  • Immunocompromised patients, including:

    1. Patients receiving systemic corticosteroids at a dose equivalent to prednisolone 20 mg/day or higher for at least 14 consecutive days.
    2. Patients who have received cytotoxic chemotherapy, biological agents, or immunosuppressive therapy within the previous 3 months.
    3. Patients with hematologic malignancies or a history of hematopoietic stem cell transplantation.
    4. Patients who have undergone solid organ transplantation (liver, kidney, heart, lung, etc.) and are currently receiving immunosuppressive therapy.
    5. Patients with congenital or primary immunodeficiency disorders.
    6. Patients with advanced HIV infection, defined as a CD4-positive T-cell count below 200 cells/μL.
  • Pregnant or breastfeeding women.

  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: a shorter course of antibiotic treatment

4 days of antibiotics including PO antibioitcs

Comparision of duration of antibiotics

Aktiver Komparator: a standard course of antibiotic treatment

7 days of antibiotics including PO antibioitcs

Comparision of duration of antibiotics

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
the clinical cure rate within 14 days after randomization
Zeitfenster: Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recurrence rate of acute cholangitis
Zeitfenster: From Day 14 to Day 30 after randomization

Recurrence of cholangitis after cure

From Day 14 to Day 30 after randomization
All-cause mortality
Zeitfenster: Within 30 days after randomization

Death regardless of cause

Within 30 days after randomization
Patient-reported health status (EQ-5D-5L)
Zeitfenster: Day 2 and Day 14 after randomization

Patient self reports regarding health status

Day 2 and Day 14 after randomization
Patient satisfaction with treatment (TSQM-II)
Zeitfenster: Day 14 after randomization

Patient self reports regarding satisfaction with treatment

Day 14 after randomization
Total duration of antibiotic use
Zeitfenster: Within 30 days after randomization

Days with antibiotics

Within 30 days after randomization
DOOR/RADAR composite outcome
Zeitfenster: Day 30 after randomization

Scoring system regarding the treatment outcomes

Day 30 after randomization

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Hospital stays
Zeitfenster: Within 30 days after randomization

Duration of hospital stay

Within 30 days after randomization
Total medical costs
Zeitfenster: Within 30 days after randomization

Total medical costs for the treatment

Within 30 days after randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Jaihwan Kim, Seoul National University Bundang Hospital

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

31. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

11. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • SNUBH-IMGPB-2026-01

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .